20 May 2013
Keywords: orion, stalevo, fails, delay, dyskinesia, early, pd
Article | 02 March 2009
Orion's Stalevo (levodopa, carbidopa and entacapone) missed the primary endpoint in a trial of 747 patients with early Parkinson's disease
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 March 2009
17 May 2013
© 2013 thepharmaletter.com